JP2011516400A5 - - Google Patents

Download PDF

Info

Publication number
JP2011516400A5
JP2011516400A5 JP2010521046A JP2010521046A JP2011516400A5 JP 2011516400 A5 JP2011516400 A5 JP 2011516400A5 JP 2010521046 A JP2010521046 A JP 2010521046A JP 2010521046 A JP2010521046 A JP 2010521046A JP 2011516400 A5 JP2011516400 A5 JP 2011516400A5
Authority
JP
Japan
Prior art keywords
composition
pharmaceutical composition
inflammatory
eye
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010521046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516400A (ja
JP5894364B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/009776 external-priority patent/WO2009025763A2/en
Publication of JP2011516400A publication Critical patent/JP2011516400A/ja
Publication of JP2011516400A5 publication Critical patent/JP2011516400A5/ja
Application granted granted Critical
Publication of JP5894364B2 publication Critical patent/JP5894364B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010521046A 2007-08-16 2008-08-15 眼および付属器組織の炎症を処置するための治療組成物 Active JP5894364B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96513507P 2007-08-16 2007-08-16
US60/965,135 2007-08-16
US13068708P 2008-06-02 2008-06-02
US61/130,687 2008-06-02
PCT/US2008/009776 WO2009025763A2 (en) 2007-08-16 2008-08-15 Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015227544A Division JP2016065089A (ja) 2007-08-16 2015-11-20 眼および付属器組織の炎症を処置するための治療組成物

Publications (3)

Publication Number Publication Date
JP2011516400A JP2011516400A (ja) 2011-05-26
JP2011516400A5 true JP2011516400A5 (https=) 2016-01-14
JP5894364B2 JP5894364B2 (ja) 2016-03-30

Family

ID=40378866

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010521046A Active JP5894364B2 (ja) 2007-08-16 2008-08-15 眼および付属器組織の炎症を処置するための治療組成物
JP2015227544A Pending JP2016065089A (ja) 2007-08-16 2015-11-20 眼および付属器組織の炎症を処置するための治療組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015227544A Pending JP2016065089A (ja) 2007-08-16 2015-11-20 眼および付属器組織の炎症を処置するための治療組成物

Country Status (5)

Country Link
US (2) US10105441B2 (https=)
EP (1) EP2187900B1 (https=)
JP (2) JP5894364B2 (https=)
AU (1) AU2008289552B2 (https=)
WO (1) WO2009025763A2 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2187900B1 (en) * 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
US10117906B2 (en) * 2009-01-09 2018-11-06 The Schepens Eye Research Institute, Inc. Methods for reducing corneal nerves damage, corneal lymphangiogenesis or immunity to corneal antigens in dry-eye associated ocular surface diseases by IL-1Ra
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
WO2011050164A1 (en) 2009-10-21 2011-04-28 Avedro, Inc. Eye therapy
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
US20110237999A1 (en) 2010-03-19 2011-09-29 Avedro Inc. Systems and methods for applying and monitoring eye therapy
US9095591B2 (en) 2010-06-28 2015-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Pharmaceutical composition for use in the treatment of glaucoma
SG186474A1 (en) * 2010-06-30 2013-02-28 Johnson & Johnson Vision Care Ophthalmic devices containing chemokine antagonists
ES2952394T3 (es) 2010-07-29 2023-10-31 Buzzard Pharmaceuticals AB Antagonistas quiméricos del receptor IL-1 de tipo I
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
WO2012148547A1 (en) * 2011-02-24 2012-11-01 The Schepens Eye Research Institute, Inc. Compositions and methods for treating inflammatory conditions of the ocular surface
US20140147413A1 (en) * 2011-02-28 2014-05-29 Dong Feng Chen Therapies That Target Autoimmunity For Treating Glaucoma And Optic Neuropathy
ES2600616T3 (es) 2011-03-14 2017-02-10 Phlogo Aps Antagonistas del receptor de la interleucina-1
US10451897B2 (en) 2011-03-18 2019-10-22 Johnson & Johnson Vision Care, Inc. Components with multiple energization elements for biomedical devices
US9044308B2 (en) 2011-05-24 2015-06-02 Avedro, Inc. Systems and methods for reshaping an eye feature
WO2012167260A2 (en) 2011-06-02 2012-12-06 Avedro, Inc. Systems and methods for monitoring time based photo active agent delivery or photo active marker presence
CA2840626A1 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
US8865685B2 (en) 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
US9812730B2 (en) 2011-08-02 2017-11-07 Johnson & Johnson Vision Care, Inc. Biocompatible wire battery
US8857983B2 (en) 2012-01-26 2014-10-14 Johnson & Johnson Vision Care, Inc. Ophthalmic lens assembly having an integrated antenna structure
US20130297023A1 (en) * 2012-05-07 2013-11-07 Hee-Jeong Im Sampen Methods and Devices For Treating Intervertebral Disc Disease
WO2013059837A2 (en) 2012-07-16 2013-04-25 Avedro, Inc. Systems and methods for corneal cross-linking with pulsed light
WO2014093870A2 (en) * 2012-12-13 2014-06-19 The Schepens Eye Research Institute, Inc. Use of c-c chemokine receptor type 7 (ccr7) inhibitors
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
CN105073112B (zh) * 2013-03-13 2017-12-29 参天制药株式会社 睑板腺功能障碍的治疗剂
EP2968468B1 (en) 2013-03-13 2021-07-14 Buzzard Pharmaceuticals AB Chimeric cytokine formulations for ocular delivery
WO2014179568A2 (en) * 2013-05-02 2014-11-06 Odin Biotech Two-layer ocular implant
EP3858356A3 (en) * 2013-05-19 2021-12-01 Avedro, Inc. Systems, methods, and compositions for cross-linking
US9498114B2 (en) 2013-06-18 2016-11-22 Avedro, Inc. Systems and methods for determining biomechanical properties of the eye for applying treatment
WO2014205145A1 (en) 2013-06-18 2014-12-24 Avedro, Inc. Systems and methods for determining biomechanical properties of the eye for applying treatment
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9793536B2 (en) 2014-08-21 2017-10-17 Johnson & Johnson Vision Care, Inc. Pellet form cathode for use in a biocompatible battery
US9383593B2 (en) 2014-08-21 2016-07-05 Johnson & Johnson Vision Care, Inc. Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators
US10627651B2 (en) 2014-08-21 2020-04-21 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers
US9599842B2 (en) 2014-08-21 2017-03-21 Johnson & Johnson Vision Care, Inc. Device and methods for sealing and encapsulation for biocompatible energization elements
US10361404B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Anodes for use in biocompatible energization elements
US9715130B2 (en) 2014-08-21 2017-07-25 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form separators for biocompatible energization elements for biomedical devices
US10381687B2 (en) 2014-08-21 2019-08-13 Johnson & Johnson Vision Care, Inc. Methods of forming biocompatible rechargable energization elements for biomedical devices
US10361405B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes
US9941547B2 (en) 2014-08-21 2018-04-10 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes and cavity structures
KR102416876B1 (ko) 2014-10-27 2022-07-05 아베드로 인코퍼레이티드 눈의 교차-결합 처리를 위한 시스템 및 방법
US10114205B2 (en) 2014-11-13 2018-10-30 Avedro, Inc. Multipass virtually imaged phased array etalon
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2016145237A1 (en) * 2015-03-11 2016-09-15 Yu Fu-Shin X Composition and methods to promote wound healing
EP3285704B1 (en) 2015-04-24 2020-11-18 Avedro Inc. Systems for photoactivating a photosensitizer applied to an eye
EP3288536B1 (en) * 2015-04-28 2019-06-26 Swedish Orphan Biovitrum AB (publ) Compositions comprising anakinra
US10028657B2 (en) 2015-05-22 2018-07-24 Avedro, Inc. Systems and methods for monitoring cross-linking activity for corneal treatments
US11207410B2 (en) 2015-07-21 2021-12-28 Avedro, Inc. Systems and methods for treatments of an eye with a photosensitizer
US10345620B2 (en) 2016-02-18 2019-07-09 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices
CN105833234A (zh) * 2016-05-20 2016-08-10 刘传彬 一种纯天然加热外敷治疗筋骨伤痛的中药组合物
EP3871682A1 (en) * 2016-10-14 2021-09-01 i.com Medical GmbH Method for establishing, restoring, and preserving homeostasis of the ocular surface
EP3565520B1 (en) 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
US12064237B2 (en) 2018-03-13 2024-08-20 Menicon Co., Ltd. Determination system, computing device, determination method, and program
EP3781175A1 (en) 2018-04-18 2021-02-24 i.com Medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
CN108707195B (zh) * 2018-05-31 2019-03-15 苏州大学 翘嘴鳜IFN-α3基因、重组蛋白、制备方法及应用
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
WO2020058504A1 (en) * 2018-09-22 2020-03-26 Novaliq Gmbh Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
US12268706B2 (en) 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
CN110437043A (zh) * 2019-08-24 2019-11-12 黄泳华 由白藜芦醇与前列腺素类似物剂构成的共晶及其在制备抗肿瘤药物中的用途
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
CN116144668A (zh) * 2023-02-13 2023-05-23 杭州吉倍思生物制药有限公司 人il-1r1基因、蛋白、同源二聚体蛋白质与用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
KR0148009B1 (ko) 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
US6858409B1 (en) * 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
EP0502956B1 (en) * 1989-11-29 1997-04-23 Amgen Boulder Inc. Production of recombinant human interleukin-1 inhibitor
WO1993007863A1 (en) * 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
US5340572A (en) * 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
US5895812A (en) * 1995-05-01 1999-04-20 The University Of Virginia Alumni Patent Foundation Diagnostic for Sjogren's syndrome
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6416753B1 (en) * 1996-03-15 2002-07-09 The General Hospital Corporation Method for modulating apoptosis
US6974682B1 (en) * 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
WO1998022130A1 (en) 1996-11-19 1998-05-28 The Schepens Eye Research Institute, Inc. Local use of il-1ra in corneal transplant rejection or disorders of the eye
ES2312179T3 (es) * 1996-12-06 2009-02-16 Amgen Inc. Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
US6455583B1 (en) 1998-05-08 2002-09-24 The University Of Miami Method for treating meibomian gland disease
US6432934B1 (en) * 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20060262813A1 (en) 1998-12-18 2006-11-23 Digital Networks North America, Inc. Multi-channel video pump
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
JP3363832B2 (ja) * 1999-05-13 2003-01-08 アルプス電気株式会社 薄膜構造体およびその製造方法
US20030007971A1 (en) * 2000-01-31 2003-01-09 Hideaki Hara Remedies for ophthalmic diseases
JP2002154985A (ja) * 2000-01-31 2002-05-28 Santen Pharmaceut Co Ltd 眼疾患治療剤
US20010041792A1 (en) * 2000-02-03 2001-11-15 Donda Russell S. Extraction of growth factors from tissue
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US6623736B2 (en) * 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
AU2003226428A1 (en) * 2002-04-18 2003-11-03 Northwestern University Encapsulation of nanotubes via self-assembled nanostructures
US7029712B1 (en) * 2002-07-17 2006-04-18 Biosyntrx Inc Treatment for dry eye syndrome
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US20050033694A1 (en) * 2003-06-03 2005-02-10 United States Postal Service. System and method for fleet card management
US20050023872A1 (en) * 2003-07-28 2005-02-03 Hetzel Thomas R. Modular seat cushion with interlocking human support and base portions and method of creating and using a seat cushion
KR100543466B1 (ko) * 2003-11-13 2006-01-20 삼성전자주식회사 영상 보간 장치 및 방법
GB0404693D0 (en) * 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
RS57852B1 (sr) 2004-04-02 2018-12-31 Swedish Orphan Biovitrum Ab Publ Postupci za smanjenje agregacije il-1ra
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
EP1858533A4 (en) * 2005-02-22 2009-09-09 Univ Johns Hopkins Med USE OF THE AMNIOTIC FLUID FOR THE TREATMENT OF DISORDERS AND OCULAR LESIONS
KR101396731B1 (ko) * 2005-03-31 2014-05-19 산텐 세이야꾸 가부시키가이샤 프로스타글란딘 Ｆ２ａ 유도체를 유효 성분으로서 함유하는망막신경세포 보호제
CN101160128B (zh) * 2005-04-13 2010-08-18 宇部兴产株式会社 含有吲唑衍生物作为有效成分的视网膜神经细胞保护剂
WO2006119292A2 (en) * 2005-04-29 2006-11-09 Henkin, Robert Methods for detection of biological substances
WO2007047969A2 (en) * 2005-10-21 2007-04-26 Amgen Inc. Methods of decreasing vascular calcification using il-1 inhibitors
WO2007056812A1 (en) * 2005-11-16 2007-05-24 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
KR20110079922A (ko) 2006-04-14 2011-07-11 노파르티스 아게 안과 장애 치료를 위한 ｉｌ－1 항체의 용도
CA2654565A1 (en) 2006-06-12 2007-12-21 Therakine Limited Topical treatment for diseases of eye surface
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
BRPI0808410A2 (pt) * 2007-02-28 2015-06-23 Aciex Therapeutics Inc Métodos e composições para normalizar secreções da glândula meibomiana
US7758190B2 (en) * 2007-06-20 2010-07-20 Tearscience, Inc. Tear film measurement
EP2187900B1 (en) * 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
EP2242504B1 (en) * 2008-01-09 2021-07-14 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders

Similar Documents

Publication Publication Date Title
JP5894364B2 (ja) 眼および付属器組織の炎症を処置するための治療組成物
JP2011516400A5 (https=)
Colligris et al. Recent developments on dry eye disease treatment compounds
US10940179B2 (en) Therapeutic compositions for the treatment of dry eye disease
EP2242504B1 (en) Therapeutic compositions for treatment of ocular inflammatory disorders
AU2010203425B2 (en) Therapeutic compositions for treatment of corneal disorders
JP2025026942A (ja) 上皮の生存と体表面の再構成を高めるための高分子量ヒアルロン酸
Skaat et al. Efficacy of topically administered rho-kinase inhibitor AR-12286 in patients with exfoliation syndrome and ocular hypertension or glaucoma
US20120014970A1 (en) Therapeutic Compositions for Treatment of Corneal Disorders
AU2014227534B2 (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CA2640986C (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CN114206849B (zh) 用于治疗非感染性眼部免疫炎性病症的治疗方法
US11306140B2 (en) Therapeutics for ocular immunoinflammatory diseases
Shetty et al. Biological cleansing: Toward improving ocular surface surgical outcomes
Mautino et al. Side effects of drugs used in ocular treatment